.Pharmacolibrary.Drugs.H_SystemicHormonalPreparationsExclSexHormonesAndInsulins.H01C_HypothalamicHormones.H01CB03_Lanreotide.Lanreotide .Pharmacolibrary.Drugs.H_SystemicHormonalPreparationsExclSexHormonesAndInsulins.H01C_HypothalamicHormones.H01CB03_Lanreotide.Lanreotide| name: | Lanreotide |
| ATC code: | H01CB03 | route: | subcutaneous |
| n-compartments | 1 |
Lanreotide is a long-acting somatostatin analog used in the treatment of acromegaly, gastroenteropancreatic neuroendocrine tumors, and symptoms associated with carcinoid syndrome. It is typically administered as a deep subcutaneous or intramuscular injection. Lanreotide is approved for use in many countries and is a clinically used drug.
Pharmacokinetic parameters in healthy adult subjects and patients with acromegaly after single deep subcutaneous injection.
Buil-Bruna, N, et al., & Trocóniz, IF (2016). Population Pharmacokinetic Analysis of Lanreotide Autogel/Depot in the Treatment of Neuroendocrine Tumors: Pooled Analysis of Four Clinical Trials. Clinical pharmacokinetics 55(4) 461–473. DOI:10.1007/s40262-015-0329-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26416534
Trocóniz, IF, et al., & Obach, R (2009). Population pharmacokinetic analysis of lanreotide Autogel in healthy subjects : evidence for injection interval of up to 2 months. Clinical pharmacokinetics 48(1) 51–62. DOI:10.2165/0003088-200948010-00004 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19071884
Yang, LP, & Keating, GM (2010). Octreotide long-acting release (LAR): a review of its use in the management of acromegaly. Drugs 70(13) 1745–1769. DOI:10.2165/11204510-000000000-00000 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20731479